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A B S T R A C T
Dose-dependent cardiotoxicity is the leading adverse reaction seen in cancer patients treated with doxorubicin.
Currently, dexrazoxane is the only approved drug that can partially protect against this toxicity in patients,
however, its administration is restricted to those patients receiving a high cumulative dose of anthracyclines.
Investigations into the mechanisms of cardiotoxicity and efforts to improve cardioprotective strategies have been
hindered by the limited availability of a phenotypically relevant in vitro adult human cardiac model system.
Here, we adapted a readily reproducible, functional 3D human multi-cell type cardiac system to emulate patient
responses seen with doxorubicin and dexrazoxane. We show that administration of two NRF2 gene inducers
namely the semi-synthetic triterpenoid Bardoxolone methyl, and the isothiocyanate sulfurophane, result in
cardioprotection against doxorubicin toxicity comparable to dexrazoxane as evidenced by an increase in cell
viability and a decrease in the production of reactive oxygen species. We further show a synergistic attenuation
of cardiotoxicity when the NRF2 inducers and dexrazoxane are used in tandem. Taken together, our data in-
dicate that the 3D spheroid is a suitable model to investigate drug induced cardiotoxicity and we reveal an
essential role of the NRF2 pathway in cardioprotection providing a novel pharmacological mechanism and
intervention route towards the alleviation of doxorubicin-induced toxicity.
1. Introduction
The anthracycline doxorubicin, although first introduced in the
1960s, continues to be a commonly used and highly effective che-
motherapeutic drug used to treat both adults and children for a wide
range of cancers including Hodgkin’s and non-Hodgkin’s lymphoma,
acute myeloid leukemia, breast and ovarian cancers. However, the
dose-dependent cardiotoxic effects of doxorubicin can limit patient
exposure and therapeutic efficacy. Even at relative low cumulative
doses (200–250mg/m2) an increase of 8% of adverse cardiac events has
been observed [1], further increasing to 26% with cumulative doses of
550–600mg/m [2]. In fact, after secondary malignancies the leading
cause of mortality in cancer patient survivors is cardiovascular disease
(CVD), with an increased eight-fold risk when compared to the general
population [3,4]. Side effects of doxorubicin include left ventricular
wall stress leading to reduction in the left ventricular ejection fraction
(LVEF), ventricular and atrial arrhythmia, chronic cardiomyopathy and
congestive heart failure.
Multiple mechanisms have been implicated in both the anti-
neoplastic and cardiotoxic action of doxorubicin, although both remain
incompletely understood [1,5]. The antineoplastic mechanisms include
the stabilisation and intercalation of doxorubicin with the topoisome-
rase II-α (TOP2 A)–DNA cleavage complex, which in turn leads to the
prevention of DNA break repair, as well as the inhibition of DNA re-
plication in rapidly proliferating cancer cells leading to cancer cell
death [6]. Further, doxorubicin has been implicated with the genera-
tion of free radicals that cause damage to DNA, cellular proteins and
mitochondria. Presently, mechanisms of cardiotoxicity include myo-
cardium injury through the generation of reactive oxygen species (ROS)
leading to subsequent membrane damage, impaired mitochondrial
function, upregulation of proteins that mediate apoptosis and disrup-
tion of calcium (Ca2+) homeostasis causing Ca2+ overload that leads to
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sarcomeric disarray and myofibril deterioration [1,6,7]. This disruption
of functioning sarcomeres highlights a potential mechanism for the loss
of contractile force that is symptomatic of patients with doxorubicin-
associated cardiotoxicity [8–10].
Experimental animal model systems have been and will continue to
be instrumental in providing important insights into the molecular basis
of cardiotoxicity and CVD. However, it is widely recognised that the
physiology of human cardiac cells differs from those of rodents; the
most commonly used in vivo experimental model [11,12]. Therefore,
research into mechanisms of CVD would be strengthened significantly
by the availability of in vitro models based on human cells. Advances in
the ability to generate cardiomyocytes from human embryonic stem
cells (hESC-CM) as well as the reprogramming from induced plur-
ipotent stem cells (iPS-CM) [1] have started to alleviate this hurdle and
provide researchers with tools to study CVD and test new drugs.
However, to date, the stem cells used in CVD research remain in an
immature state and are therefore not reflective of the phenotype of
adult cardiomyocytes [1]. Indeed, this cellular immaturity was recently
exemplified in an in vitro study in which dexrazoxane, the only drug
approved by the FDA for protection against doxorubicin induced car-
diotoxicity, was found to exacerbate the condition in iPS-CM [1,13].
Oxidative stress resulting from an increase in the generation of ROS is
one of the most widely cited mechanisms regarding the molecular
pathway underlying anthracycline induced cardiotoxicity. However, the
administration of generic anti-oxidants has been shown to result in no
alleviation of the condition [14,15]. The activation of the transcription
factor NF-E2-related factor 2 (NRF2) has been shown to antagonise
oxidative stress via the upregulation of multiple cytoprotective genes
[16,17]. This has stimulated the development of several pharmacological
activators of NRF2, including semi-synthetic triterpenoids which have
been shown to offer protection against ROS both in vivo [18–20] and in
vitro [21,22], and have subsequently entered clinical trials.
Here, we show in vivo like responses in a readily constructible 3D
microtissue spheroid in which human cardiomyocytes are grown in
combination with human cardiac fibroblasts and endothelial cells.
Consistent with this, the spheroids show a concentration-dependent
toxicity response to doxorubicin that is reduced in the presence of
dexrazoxane. Making use of this mechanistically-relevant model, we
show that Bardoxolone methyl (BARD, also known as 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-me)) as well
as Sulforaphane, an isothiocyanate from the cruciferous vegetable fa-
mily, both known NRF2 activators [16,23] can protect against doxor-
ubicin induced cardiotoxicity to a similar extent as dexrazoxane but,
have a pronounced synergistic effect when co-administered in the
presence of dexrazoxane.
2. Results
2.1. Formation of 3D cardiac spheroids
We formed monoculture 3D cardiac microtissue spheroids com-
prised of human cardiomyocytes alone and a tri-culture spheroid
comprised of human cardiomyocytes, fibroblasts and endothelial cells.
Two week-old monoculture cardiomyocyte formed loosely associated
spheroids that showed no sign of striation upon immunofluorescent-
staining using the cardiomyocyte specific marker α-actinin (Fig. 1A). In
contrast, the tri-culture formed tightly associated spheroids as early as
day 5 that displayed limited striations in addition to the presence of
endothelial cells visualised using CD31 (endothelial cell marker) and
extensive fibroblast-generated type I collagen extracellular matrix
(Fig. 1B). All markers were retained at 2 weeks in culture (Fig. 1C).
Both monoculture and tri-culture spheroids initiated beating after two
weeks of culture which coincided with the co-localization of immuno-
positive staining for HCN4 and α-actinin, showing localization of pa-
cemaker cells at this time point compared to a more dispersed staining
at 5 days (Supplemental Fig. 1). The beating rate of monoculture
spheroids was significantly lower (46.8 ± 0.86 bpm) when compared
to the tri-culture spheroids (74.8 ± 2.3 bpm; p= 0.00002, student’s t-
test) (Fig. 1D), the latter being more emulative of the beating rate range
of a resting human adult heart (60–100 bpm) [24,25].
2.2. Oxygen profiles of spheroids
To ensure that the dimensions of spheroid system permitted an ade-
quate oxygen supply throughout the system we carried out in silico pre-
dictions of oxygen (O2) profiles. Spheroids of radii 88 μm (the average
radius of spheroids in this study, blue curve/dot in Fig. 2A and B) have
only a minimal decrease in O2 with 21% O2 at the outer surface decreasing
to 16.3% O2 in the core. The core O2 % concentration then decreases
almost linearly with a further 1% O2 reduction at the core for each 7.4 μm
increase in the spheroid radius. Moreover, hypoxia (O2 less than 1%) was
only predicted in spheroids of radii greater than 190 μm (red curve/dot in
Fig. 2A and B and Cii) ensuring that the size of the spheroids used in this
study (Fig. 2Ci) have a well-maintained oxygen supply.
2.3. Cellular morphology of 3D microtissues
Since the tri-culture system showed striations and beating rates similar
to adult human cardiomyocytes, this model was examined further to
confirm cellular morphology. Electron microscopy (EM) images of the
two-week spheroids, when the spheroids first initiate beating, showed no
evidence of organized cardiac tissue (Supplemental Fig. 2). However,
spheroids maintained in culture for five weeks showed extensive α-actinin-
positive striations by immunofluorescence (Fig. 3A) and electron micro-
scopy (EM) (Fig. 3B). EM images display evidence of ultrastructure with
the alignment of Z-disks and formation of I-, H-, A- and M bands, as well as
presence of myofibrils (Mf) (Fig. 3B) and numerous mitochondria (Sup-
plemental Fig. 3). To determine spheroid functionality we examined the
activation of cardiomyocyte-expressed ryanodine receptor (RyR2) in-
tracellular calcium (Ca2+) channels in response to caffeine. Quantification
of caffeine-induced Ca2+ transients showed a significantly (p=0.02,
students t-test) increased response in the 5 week spheroids when com-
pared to those seen at the earliest stage of contraction in 2 week-old
spheroids (Fig. 3C-E). Blockade of the L-type Ca2+ channels with ver-
apamil resulted in termination of Ca2+ transients and further stimulation
with caffeine following verapamil blockage caused Ca2+ release from the
sarcoplasmic reticulum by both 2 and 5 week-old spheroids (Fig. 3F, G). In
addition, inhibition of Ca2+-ATPase (SERCA) ion-transport activity by the
addition of thapsigargin led to the cessation of caffeine-induced Ca2+
transients due to depletion of Ca2+ from the sarcoplasmic reticulum
(Fig. 3H, I). Taken together these results indicate the presence of a func-
tional sarcoplasmic reticulum in our 3D spheroid system.
2.4. Mass spectrometry analysis of cardiac cell development
We next, applied global mass spectrometry, database searching and
statistical filtering at the peptide and protein level (< 1% FDR), fol-
lowed by relative quantification based on spectral counts on both 5 day
and 5 week tri-culture spheroids to confirm the presence of known
proteins and to identify previously unannotated proteins differentially
regulated upon cellular development. Analysis of three biological re-
peats resulted in 2497 human protein identifications with a final set of
1766 passing selection criteria (< 1% FDR and ≥ 2 peptides per pro-
tein identified) (Supplemental Table 2). Comparative proteomics using
Progenesis identified 1126 differentially expressed protein clusters
(p≤ 0.05, ANOVA and/or 1.5 ≥ fold change; Fig. 4A). The hallmarks
of cardiac development is an increase in structural proteins involved in
the adult myocardium, as well as proteins involved in calcium handling
and cardiac contraction. We observed a significant increase (p < 0.05)
in expression of the structural proteins; sarcomeric α-actinin, β-myosin,
myosin binding protein C (MYBPC3), as well as an increase in myosin
light chain that is predominantly seen in adult ventricular tissue (MLC-
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Fig. 1. Verification of 3D cardiac spheroids structure A) Immunofluorescence of 2 week mono-culture spheroids show no striations after staining with α-actinin B)
immunofluorescence of tri-culture spheroids at 5 day and C) 2 weeks show visible striations which are retained as seen with α-actinin antibody, fibroblast matrix
stained with collagen I and endothelial cells with CD31 staining. All immunofluorescence images were counterstained with Hoechst (nuclei), D) Beating rate of
spheroids shows significant difference between tri-culture and monoculture spheroids (data shown as mean of beating rate ± SE, n=10 (3 independent runs);
p < 0.05, student’s t-test).
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2v, MLC1SB) [26,27] and adult atrial tissue (MLC-2a) [27,28] in 5 week
compared to 5 day spheroids (Fig. 4B). This trend was also seen in
calcium handling proteins involved in cardiac contractions; namely
Ca2+−ATPase (SERCA), phospholamban (PLN), Ryanodine receptor
(RyR2) and the sodium potassium ATPase (Na/K ATPase) (Fig. 4B). In
addition, we observed a significant (p=0.0027, ANOVA) increase in
expression of Tmem65, a recently identified maturation marker of
cardiomyocytes [29]. Gene ontology (GO) analysis calculated using
DAVID (http://david.abcc.ncifcrf.gov) of the significantly up regulated
proteins in the 5 week spheroids showed enrichment in processes as-
sociated with cardiac development such as ion transport (n= 35,
p≤0.05), muscle contraction (n= 29, p≤0.05) and heart development
(n= 18, p≤0.05; Fig. 4C). Interestingly, in agreement with the
terminally differentiated nature of mature cardiac cells, the GO term
analysis of the significantly down-regulated proteins included a de-
crease in cell motion (n= 31, p≤0.05), cell cycle process (n= 24,
p≤0.05) and cell morphogenesis (n= 17, p≤ 0.05; Fig. 4C).
Ingenuity pathway analysis (IPA) identified cardiovascular system de-
velopment and function as the top biological functional pathways (n=72,
p≤0.005) with the key nodes and their corresponding proteins shown in
Fig. 4D. IPA analysis highlighted pathways involved in the development of
cardiac tissue between pre- and post-beating cardiac spheroids. It further
highlighted a complex of proteins that were upregulated in cardiac con-
traction, which included those identified in Fig. 4D, but extended this data
to include other known regulators such as histidine-rich calcium binding
protein (HRC), a recently identified SERCA binding protein [30,31], as
well as PRKACA and CAMK2D. Upstream analysis identified known car-
diac transcription factors; MYOCD, GATA4, HAND2, and TBX5 to be ac-
tivated, inducing the up and down-regulation of proteins involved in
cardiac development and contraction [32] (Fig. 4E).
To gain a better understanding of proteins that were significantly in-
creased in cardiac development we compared all 416 proteins (≥ 1.5 fold
and p≤0.05 in the 5 week spheroid) to publically available human adult
heart microarray data [33] and found that 251 proteins were identified
with 3-fold intensity above global median. A comparison to our previously
determined chamber specific proteins identified 11 atria specific markers
and 30 ventricle specific markers enriched within this dataset [34]. Fi-
nally, in order to determine which proteins have previously been im-
plicated in disease, we searched our developmentally regulated proteins
against previous links to cardiac function on the basis of phenotype on-
tology (http://www.informatics.jax.org). This identified 75 previously
implicated proteins thereby identifying 341 previously phenotypically
uncharacterized human cardiac associated proteins (Fig. 4F).
2.5. Doxorubicin induced cardiotoxicity
Since 5 week old spheroids showed greater in vivo like morphology,
we used them to investigate doxorubicin induced cardiotoxicity.
Lightsheet-based immunofluorescence microscopy (Zeiss LightSheet
Z.1) showed that doxorubicin penetrated cells throughout the spheroid
microtissue and was not restricted to the exposed surface area resulting
in a homogeneous reporter system (Fig. 5A). Spheroids displayed a
concentration-dependent loss of cell viability in response to doxor-
ubicin, resulting in an IC50 of 0.35 μM (Fig. 5B). Moreover, pre-treat-
ment of cells with the cardioprotectant dexrazoxane diminished the
toxic effect of doxorubicin leading to an increased IC50 of 6.6 μM
(Fig. 5B). We next sought to assess the protective effects of activating
NRF2, by pre-treating cells with bardoxolone methyl (from here on
known as CDDO-me) prior to treatment with 0.001mM doxorubicin.
Under these conditions there was a significant 2-fold (p≤0.05) in-
crease in cell viability (Fig. 5C). Interestingly, when cells were pre-
treated with both dexrazoxane and CDDO-me a significant 5-fold sy-
nergetic cardioprotective response (p≤0.005) was seen when com-
pared to the doxorubicin treated cells and also a significant (p≤ 0.05)
increase in viability compared to dexrazoxane administered alone
(Fig. 5C). In order to confirm a reduction in the oxidative stress inferred
by doxorubicin we measured levels of reactive oxygen species (ROS)
which revealed a significant decrease (p≤ 0.05) in ROS levels in the
presence of dexrazoxane and CDDO-me independently (Fig. 5D) but to a
greater extent (p≤ 0.01) when administered in tandem (Fig. 5D). To
further confirm the protective effect of NRF2 induction we pre-
incubated spheroids with an alternative pharmacological activator,
sulforaphane, prior to doxorubicin treatment. This consistently showed
a significant (p≤0.05) increase in cell viability and a significant sy-
nergetic cardioprotective response (p≤ 0.005) when incubated to-
gether with dexrazoxane (Fig. 5E). No significant change of basal levels
of ATP (Supplemental Fig. 4A) or ROS (Supplemental Fig. 4B) were
seen in the presence of NRF2 stimulants in the absence of a cellular
challenge by doxorubicin indicating that the NRF2 inducers modulated
ATP only in the presence of cellular distress by doxorubicin. In keeping
with previously observed results [1] spheroids in the presence of dox-
orubicin showed a loss of integrity and increased disarray within the
sarcomeric structure of the cardiomyocytes (Fig. 5F). However, in the
presence of dexrazoxane and CDDO-me, morphological analysis showed
the retention of sarcomeric structures (Fig. 5F), consistent with the
observed cardioprotective effects of the drug combination.
In order to directly ascertain that the pre-treatment with both the
Fig. 2. Oxygen profile of spheroids A) Graphs show the
oxygen profile of spheroids with differing radii with the
outer core exposure set at atmospheric 21%. Blue curve
represents average radii of spheroids used in this study
and red indicates size that would lead to a hypoxic core B)
Graph of percentage oxygen distribution at the core of the
spheroids blue dot is the percentage in the spheroids used
in this study and red in a hypoxic core C) Heat profile of
oxygen distribution of size of spheroids i) used in this
study ii) predicted to have a hypoxic core (For inter-
pretation of the references to colour in this figure legend,
the reader is referred to the web version of this article).
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drugs did not affect the antineoplastic efficacy of doxorubicin, we ad-
ministered the corresponding concentrations to AU565 breast cancer
cells and showed no significant difference in cell viability when com-
pared to the administration of doxorubicin alone (Fig. 5G).
2.6. Role of NRF2 in cardioprotection
To confirm that CDDO-me effectively activated NRF2 signalling in
cardiac spheroids we determined the expression levels of NRF2 target
Fig. 3. Morphological and functional assess-
ment of spheroids A) Immunofluorescence
staining at 5 weeks show extensive striations (α-
actinin, red), B) Electron microscopy images of
spheroid ultrastructure showed sarcomeres; Z
disks, black arrow; H zones, M lines and I-bands;
mitochondria (m) and the presence of myofibril
bundles (Mf). Representative traces of Ca2+ re-
lease in response to 10mM caffeine in C) 2 week
spheroids and D) 5 week spheroid. E) Percentage
caffeine-induced change of peak fluorescence
intensity at 2 and 5 weeks (graph indicates
mean ± s.e after normalizing the peak fluores-
cence intensity before caffeine administration) *
denotes significant difference (p=0.02, n=3,
students t-test). Representative traces of Ca2+
release in response to 1mM verapamil before and
after administration of caffeine at F) 2 weeks and
G) 5 weeks. Representative traces of Ca2+ release
in response to 2 μM Thapsigargin before and after
administration of 10mM caffeine at H) 2 weeks
and I) 5 weeks (n=3). F, fluorescence intensity;
F0, fluorescence intensity at baseline; F/F0, F
normalized by F0. (For interpretation of the re-
ferences to colour in this figure legend, the reader
is referred to the web version of this article).
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genes by quantitative PCR (qPCR). This analysis showed a significant
synergistic induction of established NRF2 targets NQO1, SRXN1,
AKR1C1 and TXNRD1 in the presence of dexrazoxane and CDDO-me
(Fig. 6A). To confirm the involvement of the NRF2 pathway in the
cardioprotective mechanism we next used ML385, a small molecule
inhibitor of NRF2 [35]. Western blot analysis showed a significant dose
dependent decrease in NRF2 levels at the protein level (Fig. 6B and
Supplemental Fig. 5) as well as a decrease of downstream target
(caption on next page)
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TXNRD1 (Fig. 6B). Treatment of cells in the absence of doxorubicin
showed no significant change in viability of cells upon treated with
ML385 alone (Fig. 6C) or in the presence of CDDO-me or Sulforaphane
(Supplemental Fig. 6). In the presence of doxorubicin, ML385 incuba-
tion of cells pre-treated with either CDDO-me or sulforaphane led to no
significant protection against doxorubicin induced cardiotoxicity
(Fig. 6D).
3. Discussion
Chemotherapy-induced cardiotoxicity is a serious concern for estab-
lished as well as newer anticancer agents [36]. The relevance of in vitro
human cardiac models for research into cardiac disease and toxicity
clearly depends on an ability to emulate the phenotype of in vivo cardiac
tissue as closely as possible. Efforts to promote greater physiological
relevance in multiple cells types have suggested that 3D systems have
improved functionality and cellular morphology when compared to their
2D counterparts [37–40]. With this in mind, we used a multi-cell type 3D
cardiac spheroid model to investigate doxorubicin induced decrease in
viability and structural integrity. In keeping with patient observations
dexrazoxane treatment showed cardioprotection in this 3D microtissue
system leading to an increase in cell viability and the maintenance of
structural integrity in the presence of doxorubicin. This clinically-re-
levant observation, has not previously been reported for monolayer iPSC
derived cardiomyocytes with suggestions that this resulted from cellular
immaturity [1]. We show NRF2 stimulated cardioprotection to similar
levels as dexrazoxane and further showed synergistical cardioprotection
against doxorubicin induced toxicity with the co-administration of dex-
razoxane and two NRF2 inducers namely CDDO-me and sulforaphane.
Used together these drugs showed a greater significant increase in cell
viability, greater decrease in the amount of ROS generated and restora-
tion of sarcomeric structural integrity when compared to that seen with
dexrazoxane alone. This coincided with a significant increase in down-
stream targets of NRF2, which is regarded as a master regulator of de-
fence against the effects of oxidative stress [41]. The cessation of a sig-
nificant cardioprotective effect in the presence of the small molecule
NRF2 inhibitor ML385, further emphasized the involvement of NRF2 in
doxorubicin-induced cardiotoxicity.
The multi-cell type 3D cardiac system described here is an easily
reproducible model of cardiac cell development. In many of the current
systems, cardiomyocytes are used in isolation and therefore not sub-
jected to the physiological cross talk and signaling between the dif-
ferent cell types within the human heart. Indeed, it has previously been
noted that greater in vitro cardiomyocyte development occurs in the
presence of non-cardiomyocyte cells [42,43]. Although the 3D system
initiated cellular beating activity and showed the development of
striations by 2 weeks, EM analysis showed that ultrastructure devel-
opment occurred after 5 weeks. The responsive behavior of Ca2+
handling proteins through stimulation and inhibition by caffeine,
thapsiargin and verapamil confirmed that this system is functionally
active. Taken together these data indicate the presence of a functional
sarcoplasmic reticulum within the multi-cell type spheroid microtissue
system. However, it must be noted that although this system exhibits
key features of cardiac tissue, it remains somewhat electrically im-
mature as is evident from its spontaneous beating, since fully mature
cardiac cells are quiescent [44] and therefore future research will be
guided into a more in-depth understanding of this parameter. The small
size (∼88 μm in diameter) of the spheroid ensures sufficient oxygen
delivery as previously noted for the engineered biowire structure,
which have a radius of approximately 300 μm [45] and therefore these
cardiac spheroids can be maintained in culture without perfusion.
We determined that the majority of proteins found in the MS ana-
lysis of the multi-cell type spheroid microtissue system were previously
found in publically available adult heart microarray data [33]. This
included an increase in adult isoforms of an extensive range of sarco-
meric proteins including β-myosin, Troponin T- I and C- proteins, tro-
pomyosin, actin, myomesin, obscurin, nebulette, MLC2v that are es-
sential for mechanical force generation [26,44]. In addition, we
observed sarcomeric proteins previously not seen in 3D cultures such as
alpha-sarcomeric protein and myosin-binding protein C [44]. We also
found an increase in key proteins involved in contraction including
RyR2, SERCA2 and PLN, as well as a significant increase in expression
of Tmem65, an essential protein in cardiac contraction [29].
To the best of our knowledge this is the first study in which dexra-
zoxane has been administered in tandem with the NRF2 activators CDDO-
me and sulforaphane to monitor their cardioprotective potential.
Dexrazoxane, the only FDA approved cardioprotectant has been shown in
clinical trials to be effective in multiple cancer modalities in limiting the
cardiotoxic effect seen by anti-cancer drugs [46–49]. However, despite
this, it is currently only administered to women with metastatic breast
cancer who have received a cumulative dose of anthracycline of 300mg/
m2 or higher [3]. Initially, evidence from short-term clinical trials sug-
gested that administration of dexrazoxane may increase the risk of sec-
ondary malignancies or decrease the antineoplastic efficacy of the anti-
cancer drugs. These claims however were challenged in long-term follow
ups [3] with some studies now supportive of the concomitant adminis-
tration of dexrazoxane and anthracyclines to prevent cardiovascular
complications [49,50]. However, despite this the European Medicines
Agency declined widening the indication of dexrazoxane to all cancer
patients and dexrazoxane remains only available to those patients who are
expected to receive high cumulative doses of anthracyclines [50] even
though low dose exposure has been associated with cardiac damage
[1,51,52]. With this in mind, our study shows that for those patients on
low dose anthracyclines to whom dexrazoxane remains unavailable, an
alternative means of cardioprotection may be through the stimulation of
the NRF2 pathway. We show here that CDDO-me (Fig. 6A) or sulfor-
aphane (Fig. 6C) used alone increased cell viability and decreased ROS
production (Fig. 6B) to the same efficiency as dexrazoxane alone.
Several mechanisms of dexrazoxane cardioprotection have been
proposed including its ability to be a strong metal-chelating agent
which chelates free iron thereby preventing the formation of the iron-
anthracycline complexes that are responsible for the generation of su-
peroxide free radicals via redox reactions [53]. CDDO-me and sulfor-
aphane on the other hand are potent inducers of the NRF2 pathway, a
major cellular defence mechanism against oxidative stress. Used at low
concentrations (1–100 nM) CDDO-me is cytoprotective but can induce
apoptosis when administered at high concentration [54]. Here, we
show that a low concentration of CDDO-me is cardioprotective but does
not alter the chemotherapeutic efficacy of doxorubicin towards breast
cancers cells (Fig. 5G).
Fig. 4. Mass spectrometry analysis of spheroid development A) Volcano plot of the total proteins identified at 5 day and 5 weeks plotted with p-value against the
log fold change from 3 independent experiments. Differentially expressed proteins (p-value ≤ 0.05) are shown in red. Horizontal line represents p-value=0.05 and
vertical lines represent fold change of± 1.5 fold, B) Changes in levels of key proteins involved in cardiac development relative to GAPDH C) Gene Ontology (GO)
term analysis of differentially expressed proteins (p-value ≤ 0.05), red represents upregulated and green down regulated proteins, D) IPA analysis of cardiovascular
system development and function further indicated enrichment of proteins involved in development and contraction of the heart, red represents upregulated and green
down regulated proteins, E) IPA analysis of upstream regulators identified key transcription factors involved in cardiac development, orange represents significantly
up regulated proteins and pathways, blue represents down regulated pathways and green represents down regulated proteins. F) Heatmap of 416 significantly up
regulated proteins (≥ 1.5 fold and p≤ 0.05 in the 5 week spheroid) by 3-fold intensity above global median in the adult and tissue microarray, had a previously
known cardiac phenotype and were enriched in our previous atria [34] and ventricle proteome [29,34], red represents presence and black absence of proteins. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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This study clearly shows that dexrazoxane treatment does not in-
fluence NRF2 activation (Fig. 6A) but does significantly decrease ROS
production (Fig. 5D) and that CDDO-me when added alone also sig-
nificantly decreases the ROS production to an equivalent degree
(Fig. 5D) potentially through activation of downstream antioxidant
genes including SRXN1, TXNRD1 [55] and NQO1 (Fig. 6A) [56]. The
addition of CDDO-me+dexrazoxane in tandem further show a greater
significant improvement in viability and decrease in ROS than either
reagent alone. However, the addition of CDDO-me+dexrazoxane does
not significantly decrease the levels of ROS beyond that of dexrazoxane
or CDDO-me alone suggesting that addition of CDDO-me in tandem
with dexrazoxane may promote additional protection via the NRF2
(caption on next page)
L. Tomlinson, et al. Biomedicine & Pharmacotherapy 112 (2019) 108637
8
pathway through a secondary mechanism of perhaps by increasing the
glutathione levels as previously suggested [57].
Several clinical trials have focused on the preventive and therapeutic
activities of CDDO-me against a range of cancers [21] with initial ana-
lysis showing growth suppression of malignant cells at higher doses of
CDDO-me with no reported severe adverse reaction [21,54]. Amongst
several completed and ongoing clinical trials of CDDO-me, only the
BEACON trial in stage 4 chronic kidney disease patients has been ter-
minated due to an increase in the frequency of cardiac events (to 8.8%)
when compared to placebo [58]. However, post-hoc analysis on this
patient population determined those who suffered cardiac events had
previously been hospitalised for heart failure and exhibited elevated
brain natriuretic peptide (BNP) levels. Those with no previous history of
heart failure showed rates of adverse cardiac events similar to those seen
in the placebo group (2.0%) [59]. Therefore, it is unlikely that the
combined use of dexrazoxane and CDDO-me would cause cardiac events
in a suitably stratified patient population. Sulforaphane, has previously
been implicated as cardioprotective in cultured rat cardiomyocytes [60]
and phase II clinical trials in men with prostate cancer have deemed it a
safe treatment although with limited efficacy in this population [61].
To mitigate the complex cardiotoxic action of doxorubicin, a multi-
mechanistic cardioprotective approach is required. Since the adminis-
tration of dexrazoxane to patients receiving a low dose of anthracy-
clines is restricted, alternative cardioprotective methods must be de-
veloped as cardiovascular damage in these patients is well documented.
In this study we have demonstrated the potential of exploiting cardio-
protective effects of NRF2 induction to minimise doxorubicin induced
oxidative stress. We further demonstrate a synergistic protective effect
when both dexrazoxane and CDDO-me are administered in tandem.
Dexrazoxane, CDDO-me and Sulforaphane have been independently
assessed in clinical trials, but this study highlights the need for further
investigations into the value of co-administration as a novel strategy to
overcome anthracycline induced cardiotoxicity.
Fig. 5. Synergistic cardioprotection against doxorubicin toxicity by dexrazoxane and CDDO-Me A) Immunofluorescence and phase contrast Lightsheet mi-
croscopy images of doxorubicin (red) using 0.001mM doxorubicin after a 30min incubation. Three planes (x, y and z) of images show penetration of drug throughout
spheroid B) Assessment of cell viability at increasing doses of doxorubicin in 3D human spheroids in the presence and absence of 100 μM Dexrazoxane (Dex). Data
normalised to vehicle only control and vehicle + 100 μM Dex respectively, graph represent mean ± SE, n= 3 C) Fold change of cell viability seen in the presence of
0.001mM doxorubicin. Significant changes in viability seen upon pre-treatment with 100 μM Dex and 100 nM CDDO-me administered independently and in tandem.
* p≤ 0.05; ** p≤0.005 students t-test, n= 3. D) Fold change in ROS revealed a significant decrease (*p≤ 0.05) in ROS levels in the presence of dexrazoxane and
CDDO-me independently but to a greater extent (**p≤ 0.01) when administered in tandem. E) Significant changes in viability seen upon pre-treatment with 100 μM
Dex and 10 μM sulforaphane administered independently and in tandem. * p≤ 0.05; ** p≤0.005 students t-test, n= 3. F) Structural integrity was monitored using
α-actinin (red) showed a dose-dependent decrease in structure that was partially rescued in the presence of Dex and CDDO-me. G) Viability of AUG565 breast cancer
cells showed a significant decrease in viability in the presence of 0.001mM and 0.0001mM Dox. Pre-treatment with 100 μM Dex and 100 nM CDDO-me in tandem
showed no significant change to those treated with Dox alone (graphs represent mean ± SE, n= 3 for all experiments) (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article).
Fig. 6. Role of NRF2 in the cardioprotective
effects of dexrazoxane and CDDO-Me A)
qPCR analysis of established NRF2 targets
NQO1, SRXN1, AKR1C1 and TXNRD1 in cells
treated with 100 μM dexrazoxane and/or
100 nM CDDO-me (* p≤0.05; ** p≤ 0.01,
Anova, n= 3 graph represent mean fold
change ± SE) B) Immunoblot analysis of pro-
tein levels of NRF2 and downstream target
TXNRD1 in the presence of ML385 inhibitor.
C) Viability of spheroids in the presence of
ML385 alone showed no significant difference
at increased inhibitor doses (graph represent
mean ± SE n=3). D) Fold change of cell
viability seen in the presence of 0.001mM
doxorubicin. Significant changes in viability
were seen upon pre-treatment with 10μM sul-
foraphane and 100 nM CDDO-me in the ab-
sence of inhibitor (* p≤0.05 graph represent
mean ± SE, n=3). However, no significant
change was seen in the presence of ML385 in-
hibitor.
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4. Methods
4.1. Spheroid formation
Tri-culture spheroids were formed in ultra-low adhesion plates (ULA;
Corning) by mixing human embryonic stem cell-derived cardiomyocytes
(GE healthcare), human cardiac fibroblasts (Promocell) and human
cardiac endothelial (Promocell) cells at a ratio of 4:2:1. A maximum of
nine passages were permitted for the fibroblasts and endothelial cells,
whereas the cardiomyocytes were used directly from the purchased vial.
A total of 500 cells were pipetted into each well of a 96-well plate and
cells were cultured in a 1:1 v/v ratio of RPMI (Sigma) media supple-
mented with B27 (Gibco) and endothelial cell media (MV2, Promocell).
Spheroids generated from stem cell-derived cardiomyocytes alone were
formed using a total of 1000 cells per well in 96-well ULA plates with
RPMI media supplemented with B27 [62]. Spheroids were then allowed
to mature until age required for experimentation.
4.2. Immunofluorescence
Spheroids were fixed in 4% paraformaldehyde for 1 h at 4 °C, in-
cubated in permeabilisation buffer (0.5% Triton-X-100, 0.1% Tween-20 in
TBS) overnight and blocked in blocking buffer (3% BSA, 0.1% Triton-X-
100, 0.1% Tween-20 in TBS) for 2 h at room temperature. Primary anti-
bodies were diluted in blocking buffer and incubated with the spheroids
overnight at 4 °C. Spheroids were then washed three times with permea-
bilisation buffer at room temperature before incubation with secondary
antibodies diluted in blocking buffer overnight in the dark at 4 °C. Hoechst
and Phalloidin (Thermo Fisher) counterstains were diluted in permeabi-
lisation buffer and incubated with the spheroids for 1 h at room tem-
perature. Spheroids were mounted onto a glass slide with ProLong gold
(Thermo Fisher) anti-fade reagent, sealed with a coverslip and images
taken using a Zeiss Axio Observer microscope with Apo Tome. Primary
antibodies used included: α-actinin (1:400, Thermo Fisher, MA122863,
Lot#PA1809212H), CD31 (1:100, R&D systems, AF806, Lot#
DGX0314111), Collagen I (1:100, Abcam, ab21286, Lot# GR211492-4),
HCN4 (1:50, Alomore Labs, APC-052, Lot# APC052AN1725) and
Vimentin (1:100, Abcam, ab11256). Drug penetration was recorded using
a Zeiss Lightsheet Z.1 microscope as previously described [38].
4.3. Mass spectrometry
Approximately 100 spheroids at either 5 days or 5 weeks were sus-
pended in 160 μl of 25mM ammonium bicarbonate; 10 μl of 0.05%
Rapigest (Waters, Manchester) was added and spheroids shaken at
550 rpm for 10min at 80 °C. The samples were reduced by the addition
of 10 μl of 60mM Dithiothreitol (DTT) with incubation at 60 °C for
10min and then alkylated by the addition of 10 μl of 180mM iodoace-
tamide at room temperature for 30min in the dark. Trypsin (Promega UK
Ltd., Southampton, proteomics grade) 2 μg was added to the samples
followed by overnight incubation on a rotating mixer at 37 °C. The di-
gestion was terminated and Rapigest removed by acidification using 1 μl
of trifluoroacetic acid (TFA) with incubation at 37 °C for 45min followed
by centrifugation at 15,000 x g for 15min. For LC–MS/MS analysis, a
10 μl injection was analysed using an Ultimate 3000 RSLC nano system
(Thermo Scientific, Hemel Hempstead) coupled to a QExactiveHF mass
spectrometer (Thermo Scientific). The sample was loaded onto the
trapping column (Thermo Scientific, PepMap100, C18, 300 μm×5mm),
using partial loop injection, for seven minutes at a flow rate of 4 μl/min
with 0.1% (v/v) formic acid (FA). The sample was resolved on the
analytical column (Easy-Spray C18 75 μm×500mm 2 μm column)
using a gradient of 97% A (0.1% formic acid) 3% B (99.9% ACN, 0.1%
formic acid) to 70% A 30% B over 120min at a flow rate of 300 nl/min.
The data-dependent program used for data acquisition consisted of a full-
scan 60,000 resolution MS scan (AGC set to 3e6 ions with a maximum fill
time of 100ms) the 18 most abundant peaks were selected for MS/MS
using a 30,000 resolution scan (AGC set to 1e5 ions with a maximum fill
time of 45ms) with an ion selection window of 1.2 m/z and a normalised
collision energy of 28. To avoid repeated selection of peptides for MS/MS
the program used a 30 s dynamic exclusion window.
4.4. Proteomic analysis
The MS data was processed using Progenesis Q.I. for Proteomics,
version 2 (Nonlinear Dynamics, Newcastle upon Tyne, UK). Samples
were aligned according to retention time using a combination of manual
and automatic alignment. Default peak picking parameters were applied
and features with charges from 1+ to 4+ containing three or more iso-
tope peaks were retained. Database searching was performed using
Mascot (Matrix Science, London, UK) against UniHuman Reviewed and
UniMouse databases. A Mascot Generic File, created by Progenesis, was
searched against UniHuman Reviewed database. A fixed carbamido-
methyl modification for cysteine and variable oxidation modification for
methionine were specified. A precursor mass tolerance of 10 ppm and a
fragment ion mass tolerance of 0.01 Da were applied. The results were
then filtered to obtain a peptide false discovery rate of 1%.
4.5. Ca2+ imaging
Ca2+ transients were measured utilizing the Ca2+ indicator Fluo-4
(Thermo Fisher). Briefly, spheroids were incubated with 5 μM Fluo-4 AM
for 30min at 37 °C after which they were washed twice with dye-free
medium and placed back into the incubator for 30min. A Zeiss Axio
Observer microscope was used to measure the fluorescence intensity of
Fluo-4 AM treated with or without different pharmacological agents.
4.6. Cell viability
3D microtissue spheroids were incubated with varying concentra-
tions of doxorubicin (Selleck Chemicals) for 48 h and cell viability
measured using a CellTiter-Glo Luminescent Cell Viability Assay
(Promega) as described by the manufacturer’s instructions. 100 μM
Dexrazoxane was added 3 h and 100 nM CDDO-me, 10 μM sulforaphane
and 10 μM ML385, 24 h prior to doxorubicin incubation.
4.7. In silico estimates of spheroid O2
A reaction-diffusion equation was used to estimate the oxygen pro-
files within the spheroids (full details in supplementary material). A
Michaelis-Menten oxygen uptake term was assumed with maximal
oxygen consumption rates (Vmax) for the three cell types taken from a
study by Sekine et al. [63] which estimated oxygen consumption rates of
1.97×10−16, 5.28×10-17, 6.11×10-17 mol/s/cell, respectively, for
human iPSC-CM, cardiac fibroblasts (FB) and human cardiac micro-
vascular endothelial cells (EC). The Michaelis-Menten half maximal
parameter (Km) and the rate of oxygen diffusion within the spheroid
were taken to be 6.24×10-3 mol/m3 [64] and 6.33×10-10m2/sec [65],
respectively. Cell densities were calculated using the average spheroid
radius of 88 μm which comprises of a total of 498 cells in a mixed ratio of
4:2:1 for CM:FB:EC (285:142:71 cells) – giving 9.89×1013, 4.97×1013,
2.487×1013 cells/m3 for CM, FB and EC cells, respectively. These same
cell densities were then assumed for all spheroid radii considered. The
oxygen concentration at the spheroid boundary was fixed at 21% for
each spheroid radii. Radial spherical symmetry was assumed and the
steady state oxygen profiles for the spheroid interiors were calculated for
spheroid radii ranging from 50 to 200 μm.
4.8. Quantitative PCR
Total RNA was isolated from vehicle and drug treated spheroids
using the RNeasy mini kit (Qiagen), as per the manufacturer’s instruc-
tions. cDNA was synthesized using a GoScript cDNA synthesis kit
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(Promega), as per the instructions provided for a 96 well plate format.
Quantitative PCR (qPCR) analysis of NRF2, NAD(P)H dehydrogenase
quinone 1 (NQO1), Sulfiredoxin-1 (SRXN1), Aldo-keto reductase family
1 member C1 (AKR1C1), Thioredoxin reductase 1 (TXNRD1) and gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) genes was per-
formed on a Viia 7 real-time PCR instrument (Applied Biosystems)
using Power SYBR green PCR Master Mix (ThermoFisher). GAPDH was
used as a normalization control. Primer sequences are detailed in
Supplementary Table 1.
4.9. Reactive oxygen species (ROS) measurements
3D microtissue spheroids were incubated with varying concentra-
tions of doxorubicin (Selleck Chemicals) for 48 h and ROS measured
using the ROS-Glo H2O2 Assay (Promega) as described by the manu-
facturer’s instructions. 100 μM Dexrazoxane was added 3 h and 100 nM
CDDO-me or 10 μM sulforaphane, 24 h prior to doxorubicin incubation.
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